G protein-coupled receptors and inflammation resolution signaling networks in the heart: Pharmacology and potential for innovative therapeutics - PubMed
6 hours ago
- #inflammation resolution
- #G protein-coupled receptors
- #cardiac therapeutics
- Chronic, unresolved inflammation contributes to cardiovascular disease, and specialized proresolving mediators (SPMs) like lipoxins and resolvins help resolve inflammation.
- SPMs bind to G protein-coupled receptors (GPCRs) such as formyl peptide receptor 2, GPR32, GPR18, and chemerin receptor 1 to trigger intracellular proresolving actions.
- SPM-GPCR interactions show potential as therapeutic targets for heart disease, with protective effects in models involving immune and nonimmune cardiac cells like cardiomyocytes and fibroblasts.
- Downstream signaling pathways vary by cell type and disease context, and current knowledge of SPM-GPCR pharmacology in the heart is limited, requiring more research.
- Future research should focus on understanding these mechanisms in diverse cardiac cells to develop targeted therapeutics for inflammation resolution in heart disease.